Platelet Aggregation Unchanged by Lipoprotein-Associated Phospholipase A2 Inhibition: Results from an In Vitro Study and Two Randomized Phase I Trials

CONSORT 2010 Statement: Updated Guidelines for Reporting Parallel Group Randomized Trials

(2013) Kenneth F. Schulz   ANNALS OF INTERNAL MEDICINE

Secondary prevention and risk factor target achievement in a global, high-risk population with established coronary heart disease: baseline results from the STABILITY study

(2012) Ola Vedin et al.   European Journal of Preventive Cardiology

Study design and rationale for the Stabilization of pLaques usIng Darapladib—Thrombolysis in Myocardial Infarction (SOLID-TIMI 52) trial in patients after an acute coronary syndrome

(2011) Michelle L. O'Donoghue et al.   AMERICAN HEART JOURNAL

Study design and rationale for the clinical outcomes of the STABILITY Trial (STabilization of Atherosclerotic plaque By Initiation of darapLadIb TherapY) comparing darapladib versus placebo in patients with coronary heart disease

(2010) Harvey White et al.   AMERICAN HEART JOURNAL

Circulating Platelet-Activating Factor Is Primarily Cleared by Transport, Not Intravascular Hydrolysis by Lipoprotein-Associated Phospholipase A 2 / PAF Acetylhydrolase

(2010) Jinbo Liu et al.   CIRCULATION RESEARCH

Lipoprotein-associated phospholipase A2 and atherosclerosis

(2009) Robert L Wilensky et al.   CURRENT OPINION IN LIPIDOLOGY

The Effect of Darapladib on Plasma Lipoprotein-Associated Phospholipase A2 Activity and Cardiovascular Biomarkers in Patients With Stable Coronary Heart Disease or Coronary Heart Disease Risk Equivalent

(2008) Emile R. Mohler et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

Platelet-Activating Factor, PAF Acetylhydrolase, and Severe Anaphylaxis

(2008) Peter Vadas et al.   NEW ENGLAND JOURNAL OF MEDICINE